Should I Buy CRGY? CRGY 2026 Analysis

Should You Buy Crescent Energy Co (CRGY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

10.120

1 Day change

5.42%

52 Week Range

15.400

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now: momentum is turning up (positive, expanding MACD) and price is pushing above the first resistance zone (~9.87), with room toward ~10.26 next.
Options positioning is bullish-leaning (low put/call open interest), supporting a near-term continuation bias.
Hedge funds show a sharp increase in buying (+1564% QoQ), reinforcing institutional interest.
Near-term catalyst window: QDEC 2025 earnings on 2026-02-25 (After Hours) with Street expecting a return to profitability (Est. EPS 0.06).

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.
Politicians/Congress: No recent congress trading data available.

Technical Analysis

Trend/momentum: MACD histogram +0.155 and expanding → bullish momentum building.
RSI: RSI(6) ~76 → stretched/overbought in the very short term, but consistent with a breakout attempt.
Moving averages: converging → often seen ahead of a trend expansion; current momentum favors upside.
Key levels: Pivot 9.232; Resistance R1 9.866 (now being cleared), next R2 10.258; Supports S1 8.598 / S2 8.206.
Pattern-based forward bias (similar candlesticks): modest positive drift (next day ~+0.15%, next week ~+0.49%, next month ~+1.71%).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Open interest P/C = 0.33 is call-heavy → bullish positioning.
Activity: Total volume 378 with volume vs 30D avg ~38% (not a “crowded” one-day chase), while OI vs avg ~117% suggests positioning is already built.
Volatility: 30D IV ~54.99%, IV percentile 70 → options pricing implies elevated expected moves; market is paying up for protection/leveraged exposure.
Net read: bullish bias with elevated IV (better for directional stock exposure than buying expensive premium outright).

Technical Summary

Sell

Buy

Positive Catalysts

- Industry tailwind: News flow highlights a re-accelerating U.S. upstream M&A market heading into 2026, which can lift valuations across E&Ps and create strategic optionality.
- Institutional flow: Hedge funds are buying aggressively (QoQ buying up 1564%).
- Earnings catalyst: QDEC 2025 earnings (2026-02-25 AH) with consensus expecting positive EPS (Est. 0.06).
- Analyst upside exists: multiple firms still sit at $12–$13 targets (Overweight/Outperform) despite macro caution.

Neutral/Negative Catalysts

- Macro headwind: Analysts repeatedly cite near-term oil surplus/price pressure (OPEC supply + non-OPEC growth), which can cap E&P multiples.
- Execution/transition risk: Coverage notes 2026 as a transition year with production normalization and potentially slower deleveraging if oil stays soft.
- Profitability pressure in latest reported quarter despite revenue growth (loss-making quarter and margin down).
- No insider buying signal: insiders neutral recently.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $866.6M, +16.34% YoY → clear top-line growth.
Profitability: Net income -$9.51M (still a loss) and EPS -0.04 (down YoY) → earnings power not yet consistently translating.
Margin: Gross margin 20.92%, down 6.61% YoY → cost/price mix pressure despite higher revenue.
Setup into next print: market focus likely on cash flow durability, margins, and deleveraging trajectory into QDEC 2025 results.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent tone: mixed to moderately positive, but price targets have been trimmed recently due to softer oil macro.
2026-01-27 Wells Fargo: Overweight, PT cut $15 → $13 (macro pressured; prefers capital discipline).
2026-01-25 Jefferies: Hold, PT $9 (improving outlook post divestitures; wants continued execution).
2026-01-09 BMO: Market Perform, PT $10 (better margins/costs, but 2026 transition + slower deleveraging under lower oil).
2025-12-16 Evercore: Outperform, PT $13 (merger seen as step-change scale/diversification/FCF durability).
2025-12-12 Mizuho: Neutral, PT $12 (sector sentiment negative near term; value exists longer term).
2025-11-18 Piper Sandler: Overweight, PT cut $15 → $13 (ops strong but macro uninspiring).
Wall Street pros vs cons: Pros = scale/FCF durability narrative + capital discipline + execution improving; Cons = commodity macro pressure + transition year/deleveraging sensitivity to oil price.

CRGY Should I Buy